We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Dermatology

Journal Scan / Research · October 20, 2021

Efficacy and Safety of Secukinumab in Children With Moderate to Severe Plaque Psoriasis

Journal of the American Academy of Dermatology


Additional Info

Journal of the American Academy of Dermatology
A phase III open-label, randomized multicenter study to evaluate efficacy and safety of secukinumab in pediatric patients with moderate to severe plaque psoriasis: 24-week results
J Am Acad Dermatol 2021 Sep 20;[EPub Ahead of Print], N Magnolo, K Kingo, V Laquer, J Browning, A Reich, JC Szepietowski, D Keefe, R Mazur, P Ghelani, P Forrer, L Wraith, M Patekar

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading